Browsing ICR Divisions by author "Rustin, Gordon"
Now showing items 1-3 of 3
-
Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial.
Ledermann, JA; Embleton-Thirsk, AC; Perren, TJ; Jayson, GC; Rustin, GJS; et al.Background Cediranib, an oral anti-angiogenic VEGFR 1-3 inhibitor, was studied at a daily dose of 20 mg in combination with platinum-based chemotherapy and as maintenance in a randomised trial in patients with first relapse ... -
A North-West London Experience of the Impact of Treatment Related Toxicity on Clinical Outcomes of Elderly Patients with Germ Cell Tumors.
Sharma, A; Morrison, L; Milic, M; Ghose, A; Gogbashian, A; et al. (MDPI, 2022-10-11)BACKGROUND/AIM: The occurrence of germ cell tumour (GCT) in the elderly is rare, with scarce data available. The aim of this study was to understand the clinical outcomes of patients with GCT in patients aged > 45 years. ... -
Wanna Get Away? Maintenance Treatments and Chemotherapy Holidays in Gynecologic Cancers.
Madariaga, A; Rustin, GJS; Buckanovich, RJ; Trent, JC; Oza, AM (2019-01)Epithelial ovarian cancer has a very high rate of relapse after primary therapy; historically approximately 70% of patients with a complete clinical response to surgery and adjuvant chemotherapy will relapse and die of the ...